Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Ana C GalesR Ramphal

Abstract

During 1997-1999, a total of 70,067 isolates (6631 Pseudomonas aeruginosa isolates) were analyzed in the SENTRY program by geographic region and body site of infection. The respiratory tract was the most common source of P. aeruginosa. P. aeruginosa isolation rates increased during the study interval. Europe was the only region to show a significant decline in beta-lactam and aminoglycoside susceptibility rates. There was a reduction in the rates of susceptibility of Canadian isolates to imipenem and of Latin American isolates to meropenem. A total of 218 multidrug-resistant P. aeruginosa isolates (MDR-PSA; resistant to piperacillin, ceftazidime, imipenem, and gentamicin) were observed; MDR-PSA occurrence rates (percentages of all isolates) ranged from 8.2% (Latin America) to 0.9% (Canada). No antimicrobial inhibited >50% of MDR-PSA strains. Molecular characterization of selected, generally resistant strains was performed. Isolates showing unique ribogroups were found in Europe, Latin America, and the United States, but clonal spread was documented in several medical centers.

References

Jan 1, 1980·Infection·R J Holt
Apr 1, 1995·The Journal of Antimicrobial Chemotherapy·H Y ChenD M Livermore
Mar 1, 1995·Antimicrobial Agents and Chemotherapy·N MasudaS Ohya
Nov 1, 1995·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C DibV Jarlier
Nov 1, 1996·Antimicrobial Agents and Chemotherapy·P MugnierE Collatz
Feb 1, 1997·Antimicrobial Agents and Chemotherapy·B A Rasmussen, K Bush
Jun 1, 1997·The Journal of Antimicrobial Chemotherapy·D M Livermore
Dec 24, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·N TroilletY Carmeli
Jun 23, 1998·Diagnostic Microbiology and Infectious Disease·R N Jones, M A Pfaller
Jul 9, 1998·The Pediatric Infectious Disease Journal·J P ButteryS M Garland
Aug 26, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·H Nikaido
Aug 26, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R E Hancock
Aug 26, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J P Quinn
Aug 26, 1998·Lancet·N WoodfordD M Livermore
Aug 28, 1998·Journal of Chemotherapy·J BlahováK Kubonová
Sep 17, 1998·The Journal of Antimicrobial Chemotherapy·P Nordmann, M Guibert
Sep 17, 1998·The Journal of Antimicrobial Chemotherapy·R A StuntS G Amyes
Dec 1, 1998·International Journal of Antimicrobial Agents·L R PetersonG A Noskin
Jan 23, 1999·International Journal of Antimicrobial Agents·J M BlondeauC Misfeldt
Jan 30, 1999·Antimicrobial Agents and Chemotherapy·T KöhlerJ C Pechere
Feb 13, 1999·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·S Jalal, B Wretlind
Mar 3, 1999·The Journal of Antimicrobial Chemotherapy·G BonfiglioG Nicoletti
Mar 3, 1999·The Journal of Antimicrobial Chemotherapy·R R ReinertR Lütticken
Apr 1, 1999·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·S C LeeW B Shieh

❮ Previous
Next ❯

Citations

Nov 8, 2008·Intensive Care Medicine·Antoni TorresUNKNOWN European HAP working group
Dec 25, 2003·Burns : Journal of the International Society for Burn Injuries·Edward E TredgetSarvesh Logsetty
Mar 17, 2004·Diagnostic Microbiology and Infectious Disease·Tsai-Ling LauderdaleUNKNOWN TSAR Participating Hospitals
Dec 21, 2002·Diagnostic Microbiology and Infectious Disease·Ana C GalesUNKNOWN SENTRY Participants Group (Latin America)
May 3, 2003·International Journal of Antimicrobial Agents·D J HobanUNKNOWN Surveillance Study Research Group
Apr 26, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M A PfallerH S Sader
Feb 27, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Elisabeth ParamythiotouAntoine Andremont
Jul 14, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Reuben Ramphal
Jul 21, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas R FritscheRonald N Jones
Feb 22, 2003·Surgical Infections·P S Barie
Feb 22, 2011·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Fernanda M SilvaAna C Gales
Mar 30, 2012·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Lorena C C FehlbergAna C Gales
Dec 12, 2007·Antimicrobial Agents and Chemotherapy·Christian G GiskeUNKNOWN ReAct-Action on Antibiotic Resistance
Apr 11, 2013·Antimicrobial Agents and Chemotherapy·Karri A BauerDebra A Goff
Jan 25, 2003·Antimicrobial Agents and Chemotherapy·Giovanni Pietro GesuAnnalisa Cavallero
Nov 25, 2004·Antimicrobial Agents and Chemotherapy·Mariana CastanheiraTimothy R Walsh
Jan 28, 2005·Antimicrobial Agents and Chemotherapy·Keith Poole
Jun 28, 2005·Antimicrobial Agents and Chemotherapy·George A Pankey, Deborah S Ashcraft
Jul 6, 2012·Clinical Microbiology Reviews·Pranita D TammaLisa L Maragakis
Jul 15, 2003·Clinical Microbiology Reviews·Sergei B Vakulenko, Shahriar Mobashery
Apr 15, 2006·Clinical Microbiology Reviews·Deirdre ChurchRobert Lindsay
Jun 29, 2002·Journal of Clinical Microbiology·Flávia Lúcia Piffano Costa PellegrinoBeatriz Meurer Moreira
Aug 21, 2003·The British Journal of Ophthalmology·M Daniell
Apr 6, 2002·American Journal of Respiratory and Critical Care Medicine·Jean Chastre, Jean-Yves Fagon
Aug 28, 2010·BMC Pulmonary Medicine·Marya D ZilberbergAndrew F Shorr

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.